Caseware UK (AP4) 2024.0.164 2024.0.164 2025-03-312025-05-302025-03-312025-05-30The tax expense for the year comprises current and deferred tax. The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income. Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that: The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.No description of principal activityThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.32024-04-01false3truetruefalse 14749764 2024-04-01 2025-03-31 14749764 2023-03-22 2024-03-31 14749764 2025-03-31 14749764 2024-03-31 14749764 c:Director1 2024-04-01 2025-03-31 14749764 c:Director2 2024-04-01 2025-03-31 14749764 c:RegisteredOffice 2024-04-01 2025-03-31 14749764 d:OfficeEquipment 2024-04-01 2025-03-31 14749764 d:OfficeEquipment 2025-03-31 14749764 d:OfficeEquipment 2024-03-31 14749764 d:OfficeEquipment d:OwnedOrFreeholdAssets 2024-04-01 2025-03-31 14749764 d:CurrentFinancialInstruments 2025-03-31 14749764 d:CurrentFinancialInstruments 2024-03-31 14749764 d:CurrentFinancialInstruments d:WithinOneYear 2025-03-31 14749764 d:CurrentFinancialInstruments d:WithinOneYear 2024-03-31 14749764 d:ShareCapital 2025-03-31 14749764 d:ShareCapital 2024-03-31 14749764 d:RetainedEarningsAccumulatedLosses 2025-03-31 14749764 d:RetainedEarningsAccumulatedLosses 2024-03-31 14749764 c:OrdinaryShareClass1 2024-04-01 2025-03-31 14749764 c:OrdinaryShareClass1 2025-03-31 14749764 c:OrdinaryShareClass1 2024-03-31 14749764 c:OrdinaryShareClass2 2024-04-01 2025-03-31 14749764 c:OrdinaryShareClass2 2025-03-31 14749764 c:OrdinaryShareClass2 2024-03-31 14749764 c:OrdinaryShareClass3 2024-04-01 2025-03-31 14749764 c:OrdinaryShareClass3 2025-03-31 14749764 c:OrdinaryShareClass3 2024-03-31 14749764 c:OrdinaryShareClass4 2024-04-01 2025-03-31 14749764 c:OrdinaryShareClass4 2025-03-31 14749764 c:OrdinaryShareClass4 2024-03-31 14749764 c:OrdinaryShareClass5 2024-04-01 2025-03-31 14749764 c:OrdinaryShareClass5 2025-03-31 14749764 c:OrdinaryShareClass5 2024-03-31 14749764 c:FRS102 2024-04-01 2025-03-31 14749764 c:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 14749764 c:FullAccounts 2024-04-01 2025-03-31 14749764 c:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 14749764 d:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2024-04-01 2025-03-31 14749764 d:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2025-03-31 14749764 d:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2024-03-31 14749764 e:PoundSterling 2024-04-01 2025-03-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 14749764









CB NEUROLOGY LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 MARCH 2025

 
CB NEUROLOGY LIMITED
 
 
COMPANY INFORMATION


Directors
C M H Brierley 
I Brierley 




Registered number
14749764



Registered office
7 The Close

Norwich

Norfolk

NR1 4DJ




Accountants
MA Partners LLP
Chartered Accountants

7 The Close

Norwich

Norfolk

NR1 4DJ





 
CB NEUROLOGY LIMITED
 

CONTENTS



Page
Accountants' report
 
 
1
Balance sheet
 
 
2 - 3
Notes to the financial statements
 
 
4 - 9


 
CB NEUROLOGY LIMITED
 
 
  
CHARTERED ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF CB NEUROLOGY LIMITED
FOR THE YEAR ENDED 31 MARCH 2025

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of CB Neurology Limited for the year ended 31 March 2025 which comprise the Balance sheet and the related notes from the Company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW)we are subject to its ethical and other professional requirements which are detailed at https://www.icaew.com /regulation.

This report is made solely to the Board of directors of CB Neurology Limited, as a body, in accordance with the terms of our engagement letter dated 12 May 2023Our work has been undertaken solely to prepare for your approval the financial statements of CB Neurology Limited and state those matters that we have agreed to state to the Board of directors of CB Neurology Limited, as a body, in this report in accordance with ICAEW Technical Release TECH07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than CB Neurology Limited and its Board of directors, as a body, for our work or for this report. 

It is your duty to ensure that CB Neurology Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of CB Neurology Limited. You consider that CB Neurology Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or review of the financial statements of CB Neurology Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

  





MA Partners LLP
 
Chartered Accountants
  
7 The Close
Norwich
Norfolk
NR1 4DJ

30 May 2025
Page 1

 
CB NEUROLOGY LIMITED
REGISTERED NUMBER: 14749764

BALANCE SHEET
AS AT 31 MARCH 2025

2025
2024
Note
£
£

Fixed assets
  

Tangible assets
 4 
157
-

  
157
-

Current assets
  

Debtors: amounts falling due within one year
 5 
7,181
3,401

Cash at bank and in hand
  
94,119
61,265

  
101,300
64,666

Creditors: amounts falling due within one year
 6 
(32,852)
(40,367)

Net current assets
  
 
 
68,448
 
 
24,299

Total assets less current liabilities
  
68,605
24,299

Provisions for liabilities
  

Deferred tax
  
(39)
-

  
 
 
(39)
 
 
-

Net assets
  
68,566
24,299


Capital and reserves
  

Called up share capital 
 7 
100
100

Profit and loss account
  
68,466
24,199

  
68,566
24,299


Page 2

 
CB NEUROLOGY LIMITED
REGISTERED NUMBER: 14749764
    
BALANCE SHEET (CONTINUED)
AS AT 31 MARCH 2025

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 30 May 2025.






C M H Brierley
Director

The notes on pages 4 to 9 form part of these financial statements.

Page 3

 
CB NEUROLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

1.


General information

The Company is a private company limited by shares. It is both incorporated and domiciled in England and Wales. The registered office is 7 The Close, Norwich, Norfolk, NR1 4DJ.
The Company's principal activity is that of neurology consultancy services and the Company's principal place of activity is Norfolk.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Turnover comprises revenue recognised by the Company in respect of neurology consultancy services supplied during the year.

 
2.3

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the Company in independently administered funds.

 
2.4

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. The current income tax charge is  calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the  balance sheet date in the countries where the Company operates and generates income.
Deferred tax balances are recognised in respect of all timing differences that have originated but not  reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met. 
 
Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted  by the balance sheet date.

Page 4

 
CB NEUROLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

2.Accounting policies (continued)

 
2.5

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Office equipment
-
3 years straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.6

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.7

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.8

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.9

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Company's Balance sheet when the Company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
 

Page 5

 
CB NEUROLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

2.Accounting policies (continued)


2.9
Financial instruments (continued)

Basic financial assets

Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other debtors due with the operating cycle fall into this category of financial instruments.

Other financial assets

Other financial assets, which includes investments in equity instruments which are not classified as subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the recognised transaction price. Such assets are subsequently measured at fair value with the changes in fair value being recognised in the profit or loss. Where other financial assets are not publicly traded, hence their fair value cannot be measured reliably, they are measured at cost less impairment.

Impairment of financial assets

At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss. 

Financial assets are impaired when events, subsequent to their initial recognition, indicate the estimated future cash flows derived from the financial asset(s) have been adversely impacted. The impairment loss will be the difference between the current carrying amount and the present value of the future cash flows at the asset(s) original effective interest rate.

If there is a favourable change in relation to the events surrounding the impairment loss then the impairment can be reviewed for possible reversal. The reversal will not cause the current carrying amount to exceed the original carrying amount had the impairment not been recognised. The impairment reversal is recognised in the profit or loss.

Basic financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other creditors, bank loans and other loans are initially measured at their transaction price (adjusting for transaction costs except in the initial measurement of financial liabilities that are subsequently measured at fair value through profit and loss). When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future payments discounted at a market rate of interest, discounting is omitted where the effect of discounting is immaterial.
Page 6

 
CB NEUROLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

2.Accounting policies (continued)


2.9
Financial instruments (continued)


Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Trade creditors are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade creditors are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.

Derecognition of financial instruments

Derecognition of financial assets

Financial assets are derecognised when their contractual right to future cash flow expire, or are settled, or when the Company transfers the asset and substantially all the risks and rewards of ownership to another party. If significant risks and rewards of ownership are retained after the transfer to another party, then the Company will continue to recognise the value of the portion of the risks and rewards retained.

Derecognition of financial liabilities

Financial liabilities are derecognised when the Company's contractual obligations expire or are discharged or cancelled.


 
2.10

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 3 (2024: 3).

Page 7

 
CB NEUROLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

4.


Tangible fixed assets





Office equipment

£



Cost or valuation


Additions
235



At 31 March 2025

235



Depreciation


Charge for the year on owned assets
78



At 31 March 2025

78



Net book value



At 31 March 2025
157



At 31 March 2024
-


5.


Debtors

2025
2024
£
£


Trade debtors
3,685
-

Other debtors
-
10

Called up share capital not paid
-
20

Prepayments and accrued income
3,496
3,371

7,181
3,401


Page 8

 
CB NEUROLOGY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

6.


Creditors: Amounts falling due within one year

2025
2024
£
£

Corporation tax
18,026
11,253

Other taxation and social security
157
-

Other creditors
11,574
26,295

Accruals and deferred income
3,095
2,819

32,852
40,367



7.


Share capital

2025
2024
£
£
Allotted, called up and fully paid



35 (2024 - 35) A Ordinary shares of £1.00 each
35
35
35 (2024 - 35) B Ordinary shares of £1.00 each
35
35
10 (2024 - ) C Ordinary shares of £1.00 each
10
-
10 (2024 - ) D Ordinary shares of £1.00 each
10
-
10 (2024 - 10) E Ordinary shares of £1.00 each
10
10

100

80

Allotted, called up and partly paid



0 (2024 - 10) C Ordinary shares of £1.00 each
-
10
0 (2024 - 10) D Ordinary shares of £1.00 each
-
10

-

20





8.


Related party transactions

As at 31 March 2025, the Company owed the directors £10,230 (2024: £4,945).

 
Page 9